Improving diagnosis and treatment of gastrointestinal stromal tumor (GIST) patients: Results from the Dutch GIST Registry

Author(s):
Farag-Kal, S.
Published
2020
Publication type
Doctoral Thesis

Abstract

Gastrointestinal stromal tumor (GIST) is a rare mesenchymal malignancy in the gastrointestinal tract. Since the introduction of imatinib in 2002, a tyrosine kinase inhibitor (TKI) that targets Bcr-Abl, KIT and PDGFR, treatment of patients with advanced GIST has been spectacularly improved. In this rapidly evolving field, more insight is needed the treatment and follow-up of GIST patients. The focus for this thesis is on treatment strategies and follow-up in GIST patients in daily clinical practice using a large comprehensive multicenter database.

Gastrointestinal stromal tumorGISTImatinibTyrosine kinase inhibitors
Defense date
2020-09-16
Language
English
Supervisor(s)
Gelderblom, A.J.
Advisor(s)
Steeghs, N.
Committee member(s)
Hage, J.A. van der; Hoeven, J.J.M. van der; Oosten, A.W.; Oostmerssen, G. van
Qualification
Ph.D.
Degree granting institution
Faculty of Medicine, Leiden University Medical Center [LUMC], Leiden University, Leiden
hdl
1887/136757
ISBN(s)
9789463809207

Funding

Sponsorship
A research grant for the Dutch GIST Registry was received from Novartis, Bayer, and Pfizer. Financial support by Pfizer for the publication of this thesis is gratefully acknowledged.